Drug Development with Dr Clifton Barry

Today we speak with Dr Clifton Barry from NIH in Bethesda, Maryland who is head of the most highly cited research group in the field of TB over the past year and has made extraordinary contributions to TB drug development. Dr Barry speaks about his involvement in the PREDICT TB study, the TB Drug Accelerator and some of the most exciting drug developments in recent years.REFERENCESGreen, Simon R., et al. "Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs." Nature communications 13.1 (2022): 5992.https://predict-tb.com/Lange, Christoph, Clifton E. Barry III, and C. Robert Horsburgh Jr. "Treatments of multidrug-resistant tuberculosis: light at the end of the tunnel." American Journal of Respiratory and Critical Care Medicine 205.10 (2022): 1142-1144.Khan, RM Naseer, et al. "Distributable, metabolic PET reporting of tuberculosis." bioRxiv (2023).Cole, STea, et al. "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence." Nature 396.6707 (1998): 190-190.Finin, Peter, et al. "Chemical approaches to unraveling the biology of mycobacteria." Cell Chemical Biology 30.5 (2023): 420-435.Libardo, M. Daben J., et al. "Resistance of Mycobacterium tuberculosis to indole 4-carboxamides occurs through alterations in drug metabolism and tryptophan biosynthesis." Cell Chemical Biology 28.8 (2021): 1180-1191.Barry, Clifton E., Helena IM Boshoff, and Cynthia S. Dowd. "Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis." Current pharmaceutical design 10.26 (2004): 3239-3262.Xie, Yingda L., et al. "Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis." Science Translational Medicine 13.579 (2021): eabd7618.